AstraZeneca reported higher revenue and earnings for full-year 2025, driven by growth across its oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease businesses. Total revenue for 2025 rose 8% to 58.7 billion dollars, while product revenue, which combines product sales and alliance revenue, increased 10% to 58.6 billion dollars. Reported earnings per share climbed 45% to 6.60 dollars, and core earnings per share grew 11% to 9.16 dollars.
In the fourth quarter, total revenue rose 4% to 15.5 billion dollars, with product revenue up 10% to 15.5 billion dollars. Collaboration revenue fell sharply compared with the prior-year quarter, reflecting the absence of large sales-based milestones booked in late 2024. AstraZeneca’s gross margin was 80% in the quarter, two percentage points lower than a year earlier, partly due to 235 million dollars of royalty buyout costs related to Saphnelo and rilvegostomig.
The company issued 2026 guidance calling for total revenue to grow by a mid‑to‑high single-digit percentage and core earnings per share to rise by a low double-digit percentage at constant exchange rates, with an expected core tax rate of 18% to 22%. AstraZeneca also highlighted 16 positive Phase 3 trial readouts and 43 regulatory approvals in major regions over the past 12 months, and noted that its ordinary shares began trading on the New York Stock Exchange on 2 February 2026 under a harmonized listing structure.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!